Cantargia logo, biotechnology company developing antibody-based treatments for cancer and autoimmune diseases
About
About Cantargia Strategy Business development Board of Directors Management Team Careers
Research & development
Scientific background Our therapeutic areas Our clinical trials Our patents Publications and scientific presentations
Pipeline
Investor relations
Share information Analyst coverage Financial reports Financial calendar Event calendar Corporate governance General meetings Rights Issue
ESG
ESG Corporate Governance Whistleblowing
Newsroom
News and press releases Analyses and presentations Subscribe Media contact Media library
Contact Change language to Swedish 

Press releases

* (R) = Regulatory press releases

Mar 15, 2017

(R) Cantargia publishes year-end report for 2016

Feb 10, 2017

(R) Cantargia publishes outcome of the rights issue

Jan 17, 2017

(R) Cantargia publishes prospectus and certain new financial information

Jan 16, 2017

(R) Extraordinary general meeting in Cantargia

Jan 5, 2017

(R) Cantargia’s research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017

Dec 20, 2016

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Dec 20, 2016

(R) Cantargia announces rights issue of approximately MSEK91

Dec 19, 2016

(R) Cantargia’s development project exposed by leading scientific journal

Dec 16, 2016

(R) Cantargia and SMS-oncology conclude agreement on implementation of clinical phase I/IIa trial

Nov 21, 2016

(R) Cantargia publishes interim report for January – September 2016

<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Cantargia logo

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB